← All trials
NCT04769869
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2021
- Primary completion
- Sep 26, 2022
- Completion date
- Sep 26, 2022
- First posted
- Feb 25, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 169
- Arms / groups
- 15 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- ParexelOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.